GC
IBRX icon

Gould Capital’s ImmunityBio IBRX Stock Holding History

Gould Capital’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-117
Closed -$897 – 219
2026
Q1 		$897 Hold
117
– – ﹤0.01% 193
2025
Q4 		$232 Hold
117
– – ﹤0.01% 199
2025
Q3 		$288 Hold
117
– – ﹤0.01% 209
2025
Q2 		$309 Hold
117
– – ﹤0.01% 209
2025
Q1 		$352 Hold
117
– – ﹤0.01% 207
2024
Q4 		$300 Hold
117
– – ﹤0.01% 210
2024
Q3 		$435 Buy
+117
New +$541 ﹤0.01% 208

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Gould Capital's IBRX Position: Q2 2026 in Review

Gould Capital sold out of ImmunityBio (IBRX) in Q2 2026, closing a stake of 117 shares — an estimated $897 sold.

Gould Capital first reported a position in IBRX in Q3 2024 and held it in 7 quarters. The position peaked at $897 in Q1 2026. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • Gould Capital reported no remaining ImmunityBio position as of Q2 2026 after selling out during the quarter.
  • Gould Capital sold 117 ImmunityBio shares in Q2 2026, an estimated $897.
  • Gould Capital first reported a position in ImmunityBio in Q3 2024 and held it in 7 quarters.
  • Gould Capital's ImmunityBio position peaked at $897 in Q1 2026.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on Gould Capital's 13F filing for Q2 2026, filed 7 Aug 2026.